[go: up one dir, main page]

JO3003B1 - مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor - Google Patents

مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor

Info

Publication number
JO3003B1
JO3003B1 JOP/2011/0389A JOP20110389A JO3003B1 JO 3003 B1 JO3003 B1 JO 3003B1 JO P20110389 A JOP20110389 A JO P20110389A JO 3003 B1 JO3003 B1 JO 3003B1
Authority
JO
Jordan
Prior art keywords
imidazo
quinoline
kinase inhibitor
mtor kinase
mtor
Prior art date
Application number
JOP/2011/0389A
Other languages
English (en)
Inventor
Anthony Barda David
Margaret Mader Mary
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3003B1 publication Critical patent/JO3003B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يوفِّر الاختراع الحالي مركب إيميدازو [4،5-c]كوينولين-2-ون، أو ملح مقبول صيدلياً منه، والذي يثبَّط كلاً من PI3K وmTOR، لذا فهو يعد مفيداً في علاج السرطان.
JOP/2011/0389A 2011-01-14 2011-12-20 مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor JO3003B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161432958P 2011-01-14 2011-01-14

Publications (1)

Publication Number Publication Date
JO3003B1 true JO3003B1 (ar) 2016-09-05

Family

ID=45531593

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2011/0389A JO3003B1 (ar) 2011-01-14 2011-12-20 مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor

Country Status (39)

Country Link
US (2) US8440829B2 (ar)
EP (1) EP2663564B1 (ar)
JP (1) JP5891247B2 (ar)
KR (1) KR101561360B1 (ar)
CN (1) CN103282364B (ar)
AR (1) AR084551A1 (ar)
AU (1) AU2012205619B2 (ar)
BR (1) BR112013017672A2 (ar)
CA (1) CA2824760C (ar)
CL (1) CL2013002005A1 (ar)
CO (1) CO6731133A2 (ar)
CR (1) CR20130289A (ar)
CY (1) CY1116007T1 (ar)
DK (1) DK2663564T3 (ar)
DO (1) DOP2013000158A (ar)
EA (1) EA022163B1 (ar)
EC (1) ECSP13012764A (ar)
ES (1) ES2531891T3 (ar)
GT (1) GT201300180A (ar)
HR (1) HRP20150135T1 (ar)
HU (1) HUE024426T2 (ar)
IL (1) IL227165A (ar)
JO (1) JO3003B1 (ar)
ME (1) ME02019B (ar)
MX (1) MX2013008185A (ar)
MY (1) MY164705A (ar)
PE (1) PE20140864A1 (ar)
PH (1) PH12013501493A1 (ar)
PL (1) PL2663564T3 (ar)
PT (1) PT2663564E (ar)
RS (1) RS53828B1 (ar)
SG (1) SG191744A1 (ar)
SI (1) SI2663564T1 (ar)
SV (1) SV2013004496A (ar)
TN (1) TN2013000237A1 (ar)
TW (1) TWI518086B (ar)
UA (1) UA109921C2 (ar)
WO (1) WO2012097039A1 (ar)
ZA (1) ZA201304757B (ar)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2015073804A2 (en) * 2013-11-15 2015-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of blocking transmission of malarial parasite
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
TW201703769A (zh) 2015-05-08 2017-02-01 美國禮來大藥廠 用於癌症的組合療法
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
SG11201803903YA (en) * 2015-12-15 2018-06-28 Lilly Co Eli Combination therapy for cancer
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
ES2881801T3 (es) 2016-04-12 2021-11-30 Lilly Co Eli Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón
WO2017180385A1 (en) * 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating cancer
CA3025024A1 (en) 2016-05-20 2017-11-23 Eli Lilly And Company Combination therapy with notch and pd-1 or pd-l1 inhibitors
WO2018017410A1 (en) 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
WO2018063873A1 (en) 2016-09-27 2018-04-05 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of pancreatic cancer
US11376259B2 (en) 2016-10-12 2022-07-05 Eli Lilly And Company Targeted treatment of mature T-cell lymphoma
WO2018151836A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11202003427XA (en) 2017-11-06 2020-05-28 Juno Therapeutics Inc Combination of a cell therapy and a gamma secretase inhibitor
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CN110386932A (zh) 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
IL279329B2 (en) 2018-06-15 2025-01-01 Navitor Pharm Inc Rapamycin analogs and their uses
WO2020081329A1 (en) * 2018-10-18 2020-04-23 Camp4 Therapeutics Corporation Methods and compositions for modulating pcsk9 and angptl3 expression
JP2023506410A (ja) 2019-12-05 2023-02-16 アナクリア セラピューティクス， インコーポレイテッド ラパマイシン類似体及びその使用
CA3184212C (en) * 2020-09-21 2024-11-05 Wei Zhong 1-(3,3-DIFLUOROPIPERIDIN-4-YL)-IMIDAZO[4,5-C]QUINOLEIN-2-ONE SUBSTITUTE COMPOUNDS WITH THE ABILITY TO CROSS THE BLOOD-BRAIN BARRIER
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
AU2022421244A1 (en) 2021-12-22 2024-07-11 Camp4 Therapeutics Corporation Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
BRPI0416801A (pt) 2003-11-21 2007-01-09 Novartis Ag derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
US8158794B2 (en) * 2005-02-23 2012-04-17 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
ES2429170T3 (es) 2005-11-04 2013-11-13 3M Innovative Properties Company 1H-Imidazoquinolinas sustituidas con hidroxilo y alcoxilo y métodos
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
EP2356120B1 (en) * 2008-09-30 2016-10-12 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
JP2012528829A (ja) 2009-06-04 2012-11-15 ノバルティス アーゲー １Ｈ−イミダゾ［４，５−ｃ］キノリノン化合物
WO2010139731A1 (en) 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
JP2012532187A (ja) * 2009-06-30 2012-12-13 ピラマル・ライフ・サイエンシーズ・リミテッド イミダゾ［４，５−ｃ］キノリン誘導体ならびに腫瘍および／または炎症の治療におけるそれらの使用
BR112013013837A2 (pt) * 2010-12-06 2016-09-13 Piramal Entpr Ltd derivados de substituição de imidazoquinolina
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor

Also Published As

Publication number Publication date
ME02019B (me) 2015-05-20
US20130237562A1 (en) 2013-09-12
ES2531891T3 (es) 2015-03-20
CN103282364B (zh) 2015-06-17
SV2013004496A (es) 2017-11-07
RS53828B1 (sr) 2015-06-30
EA022163B1 (ru) 2015-11-30
KR20130116302A (ko) 2013-10-23
TN2013000237A1 (en) 2014-11-10
AR084551A1 (es) 2013-05-22
ZA201304757B (en) 2014-12-23
TWI518086B (zh) 2016-01-21
PL2663564T3 (pl) 2015-05-29
IL227165A (en) 2016-06-30
KR101561360B1 (ko) 2015-10-16
AU2012205619A1 (en) 2013-06-27
HRP20150135T1 (xx) 2015-03-13
CA2824760C (en) 2016-03-15
PH12013501493A1 (en) 2021-06-02
WO2012097039A1 (en) 2012-07-19
US8440829B2 (en) 2013-05-14
US20120184577A1 (en) 2012-07-19
EA201390823A1 (ru) 2013-12-30
AU2012205619B2 (en) 2015-05-21
PT2663564E (pt) 2015-02-24
TW201307343A (zh) 2013-02-16
EP2663564B1 (en) 2014-12-17
CN103282364A (zh) 2013-09-04
NZ611541A (en) 2015-02-27
CO6731133A2 (es) 2013-08-15
PE20140864A1 (es) 2014-07-19
EP2663564A1 (en) 2013-11-20
SG191744A1 (en) 2013-08-30
DK2663564T3 (en) 2015-01-12
SI2663564T1 (sl) 2015-01-30
ECSP13012764A (es) 2013-09-30
CA2824760A1 (en) 2012-07-19
HK1188454A1 (en) 2014-05-02
CL2013002005A1 (es) 2013-12-27
CY1116007T1 (el) 2017-01-25
JP5891247B2 (ja) 2016-03-22
BR112013017672A2 (pt) 2018-09-18
MX2013008185A (es) 2013-08-21
UA109921C2 (uk) 2015-10-26
US8658668B2 (en) 2014-02-25
CR20130289A (es) 2013-10-07
JP2014502638A (ja) 2014-02-03
HUE024426T2 (en) 2016-01-28
DOP2013000158A (es) 2013-11-30
GT201300180A (es) 2014-04-08
MY164705A (en) 2018-01-30

Similar Documents

Publication Publication Date Title
JO3003B1 (ar) مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
MX378263B (es) Terapia de combinación para el tratamiento del cáncer.
CL2013002177A1 (es) Compuestos derivados de 9h-purinas y 7h-pirrolo[2,3-d]-pirimidinas sustituidas, inhibidores de la pi3k de clase i y/o mtor; su composicon farmaceutica; su combinacion farmaceutica; y su uso en el tratamiento o la prevencion del cancer o trastornos neurodegenerativos.
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
WO2012068106A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
MX360634B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
PH12014501986B1 (en) 2-amino, 6-phenyl substituted pyrido [2,3-d] pyrimidine derivatives useful as raf kinase inhibitors
HK1216176A1 (zh) 用於治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
TN2009000400A1 (en) Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha
MX2013005826A (es) Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion.
WO2012068096A3 (en) Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2010010300A (es) Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
BR112014029705A2 (pt) composto ou sal, medicamento, métodos para inibir quinase de janus em um mamífero, e para a profilaxia ou tratamento de doenças autoimunes, e, uso de um composto ou sal
EA201591483A1 (ru) Производные имидазо[4,5-с]пиридина и пирроло[2,3-с]пиридина в качестве ингибиторов ssao
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
PH12016502353A1 (en) Pharmaceutical composition
TW201613577A (en) Pharmaceutical combinations
MX2013005819A (es) Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion.
WO2014160177A3 (en) Quinazoline inhibitors of pi3k
TH149217A (th) สารประกอบอิมิดาโซล[4,5-c]ควินอลิน-2-โอน และการใช้ของมันในรูปตัวยับยั้งคู่สำหรับ Pl3 คิเนส/MTOR
TH149217B (th) สารประกอบอิมิดาโซล[4,5-c]ควินอลิน-2-โอน และการใช้ของมันในรูปตัวยับยั้ง คู่สำหรับ Pl3 คิเนส/MTOR
UA71662U (ru) Способ лечения хронического генерализованного пародонтита